Technology area: Biotechnology & Pharmaceuticals
21 pending office actions • 14 art units • 18 examiners • 0 of 21 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Alexion Pharmaceuticals Inc. manages a portfolio with 21 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 18 distinct examiners, which suggests the company must navigate a wide variety of individual examination styles. The prosecution is further spread across 14 distinct art units, indicating a broad technical range within the pharmaceutical sector. SZPERKA, MICHAEL EDWARD is the busiest examiner for the company, currently responsible for 4 pending actions.
The presence of 18 distinct examiners for 21 pending office actions means that most applications are being reviewed by different individuals. This requires a decentralized prosecution strategy where each case is tailored to the specific examiner's requirements. With 14 distinct art units involved, the company faces diverse administrative policies and technical standards across the USPTO. The 4 pending actions assigned to SZPERKA, MICHAEL EDWARD constitute the most significant point of examiner contact for the company. Practitioners should focus on these specific matters as a key area for potential consistency while preparing for varied feedback across the other pending actions.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (14%) |
| §103 only | 4 (19%) |
| §112 only | 4 (19%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 4 (19%) |
| Multi-statute (no §101) | 5 (24%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZPERKA, MICHAEL EDWARD | 4 | 62.6% | +37.5% |
| CONSTANTINE, CHARLES Z | 1 | 59.0% | +49.3% |
| ROMERO, KRISTEN WANG | 1 | 69.8% | +30.8% |
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
| SVEIVEN, MICHAEL CAMERON | 1 | 36.0% | +49.2% |
| DEBERRY, REGINA M | 1 | 50.2% | +30.8% |
| RONEY, CELESTE A | 1 | 63.0% | +17.4% |
| HAM, JIEUN | 1 | 45.5% | +0.0% |
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17838115 | METHOD AND SYSTEM FOR IMPROVED MANAGEMENT OF GENETIC DISEASES | MINCHELLA, KAITLYN L | 59d overdue |
| 18798163 | METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS | CONSTANTINE, CHARLES Z | — |
| 18719260 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ROMERO, KRISTEN WANG | — |
| 18682330 | ASSAY METHODS FOR SCREENING INHIBITORS OF SICKLE CELL DISEASE, ß-THALASSEMIA, OR SICKLE CELL ß-THALASSEMIA, OR A PHENOTYPE THEREOF | SVEIVEN, MICHAEL CAMERON | — |
| 18682310 | METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING A COMPLEMENT ALTERNATIVE PATHWAY INHIBITOR | DEBERRY, REGINA M | — |
| 18568011 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING DERMATOMYOSITIS (DM) | ALDARONDO, DASIA ALI | — |
| 18561469 | KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME | COFFA, SERGIO | — |
| 18272906 | METHODS OF TREATING COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY USING AN ANTI-C5 ANTIBODY | LU, CHENG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292042 | METHODS OF TREATING COPPER METABOLISM-ASSOCIATED DISEASES OR DISORDERS | RONEY, CELESTE A | 51d overdue |
| 18018936 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) | SZPERKA, MICHAEL EDWARD | 17d overdue |
| 17784025 | METHODS OF TREATING PREGNANCY-ASSOCIATED ATYPICAL HEMOLYTIC UREMIC SYNDROME USING AN ANTI-C5 ANTIBODY | SZPERKA, MICHAEL EDWARD | 8d overdue |
| 18798163 | METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS | CONSTANTINE, CHARLES Z | — |
| 18719260 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ROMERO, KRISTEN WANG | — |
| 18682330 | ASSAY METHODS FOR SCREENING INHIBITORS OF SICKLE CELL DISEASE, ß-THALASSEMIA, OR SICKLE CELL ß-THALASSEMIA, OR A PHENOTYPE THEREOF | SVEIVEN, MICHAEL CAMERON | — |
| 18682310 | METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING A COMPLEMENT ALTERNATIVE PATHWAY INHIBITOR | DEBERRY, REGINA M | — |
| 18561469 | KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME | COFFA, SERGIO | — |
| Art Unit | Apps |
|---|---|
| 1641 | 6 |
| 1647 | 2 |
| 1643 | 2 |
| 1657 | 1 |
| 1624 | 1 |
| 1623 | 1 |
| 1678 | 1 |
| 1612 | 1 |
| 1658 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18798163 | METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS | CONSTANTINE, CHARLES Z | 1657 | §101§112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18719260 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ROMERO, KRISTEN WANG | 1624 | §102§103Other | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18719261 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | BAUER, BRIANNA LEE | 1623 | §112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18682330 | ASSAY METHODS FOR SCREENING INHIBITORS OF SICKLE CELL DISEASE, ß-THALASSEMIA, OR SICKLE CELL ß-THALASSEMIA, OR A PHENOTYPE THEREOF | SVEIVEN, MICHAEL CAMERON | 1678 | §101§102§103§112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18682310 | METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING A COMPLEMENT ALTERNATIVE PATHWAY INHIBITOR | DEBERRY, REGINA M | 1647 | §102§112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18292042 | METHODS OF TREATING COPPER METABOLISM-ASSOCIATED DISEASES OR DISORDERS | RONEY, CELESTE A | 1612 | §102§103§112DP | Final Rejection | 51d overdue | Pending | Jan 25, 2024 |
| 18577912 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF MYASTHENIA GRAVIS | HAM, JIEUN | 1643 | §102§112DP | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18568011 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING DERMATOMYOSITIS (DM) | ALDARONDO, DASIA ALI | 1647 | §103§112DP | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18561469 | KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME | COFFA, SERGIO | 1658 | §102§112 | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18505022 | PREPARATION OF FACTOR XA DERIVATIVES | SZPERKA, MICHAEL EDWARD | 1641 | DP | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18500675 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SZPERKA, MICHAEL EDWARD | 1641 | §112Other | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18272906 | METHODS OF TREATING COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY USING AN ANTI-C5 ANTIBODY | LU, CHENG | 1642 | §103§112Other | Final Rejection | — | Pending | Jul 18, 2023 |
| 18219138 | ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS | NATARAJAN, MEERA | 1643 | §103 | Final Rejection | 38d overdue | Pending | Jul 07, 2023 |
| 18032973 | METHOD OF CONTROLLING TOTAL SIALIC ACID CONTENT (TSAC) DURING MANUFACTURING OF ALKALINE PHOSPHATASE | RAMIREZ, DELIA M | 1652 | §102§103§112Other | Non-Final OA | — | Pending | Apr 20, 2023 |
| 18018936 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) | SZPERKA, MICHAEL EDWARD | 1641 | §112Other | Final Rejection | 17d overdue | Pending | Jan 31, 2023 |
| 18010076 | METHODS FOR TESTING ANDEXANET POTENCY | FAN, LYNN Y | 1759 | §103 | Non-Final OA | 5d overdue | Pending | Dec 13, 2022 |
| 17849793 | ANTI-C5A ANTIBODIES | HOWARD, ZACHARY C | 1674 | §112Other | Non-Final OA | — | Pending | Jun 27, 2022 |
| 17838115 | METHOD AND SYSTEM FOR IMPROVED MANAGEMENT OF GENETIC DISEASES | MINCHELLA, KAITLYN L | 1685 | §101§103§112Other | Final Rejection | 59d overdue | Pending | Jun 10, 2022 |
| 17784025 | METHODS OF TREATING PREGNANCY-ASSOCIATED ATYPICAL HEMOLYTIC UREMIC SYNDROME USING AN ANTI-C5 ANTIBODY | SZPERKA, MICHAEL EDWARD | 1641 | §103Other | Final Rejection | 8d overdue | Pending | Jun 09, 2022 |
| 17738131 | HIGH CONCENTRATION ANTI-C5 ANTIBODY FORMULATIONS | KIM, YUNSOO | 1641 | §112DP | Final Rejection | 19d | Pending | May 06, 2022 |
| 17612368 | METHODS OF TREATING VITILIGO USING AN ANTI-C5 ANTIBODY | TAYLOR, LIA ELAN | 1641 | §103Other | Non-Final OA | — | Pending | Nov 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlexion Pharmaceuticals Inc. has 21 pending office actions as of October 2026, spread across 14 art units and 18 examiners.
Michael Edward Szperka has the most, with 4 of Alexion Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
